{"id":39834,"date":"2025-08-07T18:36:08","date_gmt":"2025-08-07T16:36:08","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/08\/07\/spatial-analysis-of-the-tumor-microenvironment-in-diffuse-large-b-cell-lymphoma-reveals-clinically-relevant-cell-interactions-and-recurrent-cellular-neighborhoods\/"},"modified":"2025-08-07T18:36:08","modified_gmt":"2025-08-07T16:36:08","slug":"spatial-analysis-of-the-tumor-microenvironment-in-diffuse-large-b-cell-lymphoma-reveals-clinically-relevant-cell-interactions-and-recurrent-cellular-neighborhoods","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/08\/07\/spatial-analysis-of-the-tumor-microenvironment-in-diffuse-large-b-cell-lymphoma-reveals-clinically-relevant-cell-interactions-and-recurrent-cellular-neighborhoods\/","title":{"rendered":"Spatial Analysis of the Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Reveals Clinically Relevant Cell Interactions and Recurrent Cellular Neighborhoods"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Aug 7. doi: 10.1158\/2326-6066.CIR-24-1163. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Recent studies have explored the composition of tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL) However, cell-to-cell interactions, along with the spatial organization of DLBCL TME and their impact on patient outcomes, have remained poorly characterized. We ap-plied multiplexed immunofluorescence, cell phenotyping, and neighborhood analysis to investigate 1,218,756 single cells in 99 samples from patients with primary DLBCL. We identified 17 cell pheno-types and 10 recurrent cellular neighborhoods (RCNs) across samples, subdividing DLBCLs into immune-poor areas and areas with diverse immune cell infiltrates. Avoidance of B cells and PD-1+ T cells was associated with less aggressive clinical characteristics and favorable survival. Like-wise, the proximity of CD8+ T cell-rich and immune-poor RCNs translated to favorable, and the proximity of PD-L1+ B cell-rich and CD8+ T cell-rich RCNs to unfavorable patient outcomes. Our findings provide insights into the spatial interactions and organization of DLBCL TME with implica-tions for patient outcomes.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40772779\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20250807123605&amp;v=2.18.0.post9+e462414\">40772779<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-1163\">10.1158\/2326-6066.CIR-24-1163<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Aug 7. doi: 10.1158\/2326-6066.CIR-24-1163. Online ahead of print. ABSTRACT Recent studies have explored the composition of tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL) However, cell-to-cell interactions, along with the spatial organization of DLBCL TME and their impact on patient outcomes, have remained poorly characterized. We ap-plied multiplexed immunofluorescence, cell &#8230; <a title=\"Spatial Analysis of the Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Reveals Clinically Relevant Cell Interactions and Recurrent Cellular Neighborhoods\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/08\/07\/spatial-analysis-of-the-tumor-microenvironment-in-diffuse-large-b-cell-lymphoma-reveals-clinically-relevant-cell-interactions-and-recurrent-cellular-neighborhoods\/\" aria-label=\"Read more about Spatial Analysis of the Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Reveals Clinically Relevant Cell Interactions and Recurrent Cellular Neighborhoods\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-39834","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/39834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=39834"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/39834\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=39834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=39834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=39834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}